DENVER, Colo., Apr 15, 2025 (247marketnews.com) -Today’s top news and trades include weight loss and super fibers.
MetaVia (NASDAQ:MTVA) unveiled Phase 1 MAD trial results for DA-1726, its novel 3:1 ratio GLP-1/glucagon dual receptor agonist aimed at obliterating obesity. This 4-week trial slashed up to 6.3% body weight and 3.9 inches off waists, signaling a potential best-in-class contender in an estimated $100 billion obesity drug market.
DA-1726, a once-weekly injectable oxyntomodulin (OXM) analog, wowed in the 28-day, 36-subject trial (NCT 06252220), hitting a mean 4.3% weight loss at the 32 mg dose by Day 26 (p=0.0005), with no titration needed.
However, that wasn’t today’s only weight loss breakthrough news.
Skye Bioscience (NASDAQ:SKYE) reported that its nimacimab CB1 antibody, paired with tirzepatide, slashed an astonishing 30% body weight in a preclinical obesity model. This murine diet-induced obesity (DIO) study, coupled with in vitro potency data trumping monlunabant, catapults SKYE into the estimated $100 billion obesity drug arena.
In the 25-day DIO trial, nimacimab alone delivered a robust 23.5% weight loss, matching heavyweights monlunabant and tirzepatide.
New in vitro data seals the deal, showing nimacimab’s non-competitive allosteric CB1 binding outmuscles monlunabant’s weaker competitive inhibition, even against high CB1 agonist levels.
Punit Dhillon, Skye’s CEO, said, “This new preclinical study highlights that a truly peripherally-restricted CB1 inhibitor—nimacimab—effectively drives weight loss in a DIO model. Nimacimab compared favorably to and provided significant additive weight loss when combined with GLP-1-targeted drugs like tirzepatide. Using higher doses, this study builds on our previous preclinical DIO data in human CB1 knock-in mice that showed significant dose-dependent weight loss. Biomarker analyses demonstrated that nimacimab-driven weight loss was associated with beneficial changes in key hormones, glycemic control, and inflammatory markers.
Kraig Biocraft Laboratories (OTCQB:KBLB), the spider silk technology titan, is rolling out a next-generation gene-splicing platform that’s catapulting its biotech prowess to new heights. This cutting-edge system is already validated with a brand-new transgenic silkworm marks the next step for Kraig Labs.
Kraig Labs’ new molecular biology platform harnesses advanced gene-editing tools, slashing DNA manipulation to unprecedented precision and speed to create a freshly minted transgenic silkworm, now in testing for commercial-grade spider silk that’s tougher than steel and eco-friendly to boot, boosting efficiency and performance for technical textiles, defense, apparel, and medical applications.
Kim Thompson, Kraig’s CEO and founder, commented, “Our adaption of this technology represents a transformative advancement for Kraig Labs and our entire molecular biology program. With this platform in place, we are dramatically expanding the speed, scope, and sophistication of our genetic engineering capabilities. The successful creation of new transgenics using this system confirms its effectiveness. We are experimenting with two such platforms and will likely adopt one of them for all of our ongoing and future commercial silkworm development.”
ARB IOT (NASDAQ:ARBB) reported, during yesterday’s afterhours trading session, that it entered into a $53 million contract to deliver AI data center server solutions to Whizzl Group.
Mural Oncology (NASDAQ:MURA) is halting its clinical work plans on pivoting by launching a high-stakes hunt for strategic alternatives to maximize shareholder value, backed by a hefty cash pile.
Synergy CHC (NASDAQ:SNYR) is running strong today, as a momentum mover.
Please go to https://247marketnews.com/kblb-disclosure/ for disclaimer information.
The post Today’s Top News and Trades- SKYE, KBLB, MTVA, ARBB, MURA, SNYR appeared first on 24/7 MarketNews.